Novel therapies for non-small cell lung cancer

Jessica S. Donington, Chi Wan Koo, Marc S. Ballas

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Lung cancer is the leading cause of cancer-related death in the United States. Emerging technologies for the treatment of early-stage non-small cell lung cancer are currently focused on less invasive approaches to obtaining local tumor control, including minimally invasive and less radical resections, as well as image-guided ablative therapies. Targeted chemotherapeutic agents represent the newest area of treatment for advanced non-small cell lung cancer. These novel agents capitalize on our increased understanding of the diverse biology of the disease. Each of these advanced modalities works best for only a small subset of the population with lung cancer, and efficacious use is highly dependent on appropriate patient selection.

Original languageEnglish (US)
Pages (from-to)175-185
Number of pages11
JournalJournal of Thoracic Imaging
Volume26
Issue number2
DOIs
StatePublished - May 2011
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Lung Neoplasms
Patient Selection
Neoplasms
Technology
Therapeutics
Population

Keywords

  • bevacizumab
  • epidermal growth factor receptor
  • Non-small cell lung cancer
  • pemetrexed
  • percutaneous ablative therapy
  • stereotactic body radiation therapy
  • sublobar resection
  • targeted therapies

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Pulmonary and Respiratory Medicine

Cite this

Novel therapies for non-small cell lung cancer. / Donington, Jessica S.; Koo, Chi Wan; Ballas, Marc S.

In: Journal of Thoracic Imaging, Vol. 26, No. 2, 05.2011, p. 175-185.

Research output: Contribution to journalArticle

Donington, Jessica S. ; Koo, Chi Wan ; Ballas, Marc S. / Novel therapies for non-small cell lung cancer. In: Journal of Thoracic Imaging. 2011 ; Vol. 26, No. 2. pp. 175-185.
@article{4dcd1558ac77469cba79a6c9c87b49cb,
title = "Novel therapies for non-small cell lung cancer",
abstract = "Lung cancer is the leading cause of cancer-related death in the United States. Emerging technologies for the treatment of early-stage non-small cell lung cancer are currently focused on less invasive approaches to obtaining local tumor control, including minimally invasive and less radical resections, as well as image-guided ablative therapies. Targeted chemotherapeutic agents represent the newest area of treatment for advanced non-small cell lung cancer. These novel agents capitalize on our increased understanding of the diverse biology of the disease. Each of these advanced modalities works best for only a small subset of the population with lung cancer, and efficacious use is highly dependent on appropriate patient selection.",
keywords = "bevacizumab, epidermal growth factor receptor, Non-small cell lung cancer, pemetrexed, percutaneous ablative therapy, stereotactic body radiation therapy, sublobar resection, targeted therapies",
author = "Donington, {Jessica S.} and Koo, {Chi Wan} and Ballas, {Marc S.}",
year = "2011",
month = "5",
doi = "10.1097/RTI.0b013e3182161709",
language = "English (US)",
volume = "26",
pages = "175--185",
journal = "Journal of Thoracic Imaging",
issn = "0883-5993",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Novel therapies for non-small cell lung cancer

AU - Donington, Jessica S.

AU - Koo, Chi Wan

AU - Ballas, Marc S.

PY - 2011/5

Y1 - 2011/5

N2 - Lung cancer is the leading cause of cancer-related death in the United States. Emerging technologies for the treatment of early-stage non-small cell lung cancer are currently focused on less invasive approaches to obtaining local tumor control, including minimally invasive and less radical resections, as well as image-guided ablative therapies. Targeted chemotherapeutic agents represent the newest area of treatment for advanced non-small cell lung cancer. These novel agents capitalize on our increased understanding of the diverse biology of the disease. Each of these advanced modalities works best for only a small subset of the population with lung cancer, and efficacious use is highly dependent on appropriate patient selection.

AB - Lung cancer is the leading cause of cancer-related death in the United States. Emerging technologies for the treatment of early-stage non-small cell lung cancer are currently focused on less invasive approaches to obtaining local tumor control, including minimally invasive and less radical resections, as well as image-guided ablative therapies. Targeted chemotherapeutic agents represent the newest area of treatment for advanced non-small cell lung cancer. These novel agents capitalize on our increased understanding of the diverse biology of the disease. Each of these advanced modalities works best for only a small subset of the population with lung cancer, and efficacious use is highly dependent on appropriate patient selection.

KW - bevacizumab

KW - epidermal growth factor receptor

KW - Non-small cell lung cancer

KW - pemetrexed

KW - percutaneous ablative therapy

KW - stereotactic body radiation therapy

KW - sublobar resection

KW - targeted therapies

UR - http://www.scopus.com/inward/record.url?scp=79955561341&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955561341&partnerID=8YFLogxK

U2 - 10.1097/RTI.0b013e3182161709

DO - 10.1097/RTI.0b013e3182161709

M3 - Article

C2 - 21508738

AN - SCOPUS:79955561341

VL - 26

SP - 175

EP - 185

JO - Journal of Thoracic Imaging

JF - Journal of Thoracic Imaging

SN - 0883-5993

IS - 2

ER -